Lys125

Site Information
EskVFyLkMkGDyyR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3649474
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 )
Disease tissue studied:	colorectal cancer ( 9 ) , colorectal carcinoma ( 9 ) , gastric cancer ( 5 ) , lung cancer ( 1 , 2 ) , non-small cell lung cancer ( 3 , 4 , 6 , 7 ) , non-small cell lung adenocarcinoma ( 1 , 4 ) , non-small cell squamous cell lung carcinoma ( 7 ) , small-cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 1 , 10 ) , DMS79 (pulmonary) ( 2 ) , HCT116 (intestinal) ( 9 , 11 ) , Jurkat (T lymphocyte) ( 10 ) , lung ( 2 ) , MKN-45 (gastric) ( 5 ) , MV4-11 (macrophage) ( 10 ) , NCI-H128 (pulmonary) ( 2 ) , NCI-H1417 (pulmonary) ( 2 ) , NCI-H1703 (squamous) ( 7 ) , NCI-H209 (pulmonary) ( 2 ) , NCI-H2228 (pulmonary) ( 4 ) , NCI-H3122 (pulmonary) ( 3 ) , NCI-H3255 (pulmonary) ( 6 ) , NCI-H524 (pulmonary) ( 2 )

Upstream Regulation
Treatments:	vorinostat ( 10 )

References
1	Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520 25825284 Curated Info
2	Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
4	Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
9	Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
11	Li Y (2006) CST Curation Set: 2000; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'\|\|' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info